Cat. No. | Product name | CAS No. |
A020 |
Tocilizumab
Featured
Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor。 |
375823-41-9 |
A021 |
Trastuzumab
Featured
Trastuzumab (anti-human HER2) is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2. |
180288-69-1 |
A022 |
Ustekinumab
Featured
Ustekinumab is human monoclonal antibody to a polypeptide found on interleukin-12 and -23 that is used to treat autoimmune conditions and is approved for use in severe psoriasis. |
815610-63-0 |
A023 |
Vedolizumab
Featured
Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease. |
943609-66-3 |
DC39258 |
BAY1217224
Featured
BAY1217224 is a highly potent, orally bioavailable, neutral, non-prodrug thrombin inhibitor with IC50 of 0.7 nM.BAY1217224, has reached first clinical trials, which have confirmed the desired pharmacokinetic properties. |
|
DC39261 |
LEO 39652
Featured
LEO 39652 is a novel PDE4 inhibitor with IC50 of 3.8 nM and selected as a clinical candidate as it is potent and rapidly degraded by blood and liver to inactive metabolites. |
1445656-91-6 |
A026 |
Mepolizumab
Featured
Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). |
196078-29-2 |
A030 |
Etanercept
Featured
Etanercept is a soluble TNF receptor fusion protein and acts as a TNF inhibitor. |
185243-69-0 |
A024 |
Pertuzumab
Featured
Pertuzumab, a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer. |
380610-27-5 |
A025 |
Natalizumab
Featured
Natalizumab is a recombinant, humanized monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses. |
189261-10-7 |
A029 |
Efmoroctocog alfa
Featured
Efmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life compared with conventional factor VIII (FVIII) preparations, including recombinant FVIII (rFVIII) products such as Moroctocog alfa1. It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It is suitable for all age groups. Haemophilia A is a rare bleeding disorder associated with a slow clotting process caused by the deficiency of factor VIII. Patients with this disorder are more susceptible to recurrent bleeding episodes and excessive bleeding following minor traumatic injuries or surgical procedures 1. Prophylactic treatment may dramatically improve the management of severe haemophilia A in the future by reducing joint bleeding and other hemorrhages that cause chronic pain and disability to patients 1,2. Prophylaxis has also shown to reduce the formation of neutralizing anti-FVIII antibodies, or inhibitors 2. Factor VIII is a blood coagulant factor involved in the intrinsic pathway to form fibrin, or a blood clot. Efmoroctocog alfa is a first commercially available rFVIII-Fc fusion protein (rFVIIIFc) where the conjugated molecule of rFVIII to polyethylene glycol is covalently fused to the dimeric Fc domain of human immunoglobulin G1, a long-lived plasma protein Label. The B domain of factor VIII is deleted. In animal models of haemophilia, efmoroctocog alfa demonstrated an approximately two-fold longer t½ than commercially available rFVIII products 1. |
1270012-79-7 |
A027 |
Panitumumab
Featured
Panitumumab, formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans). |
339177-26-3 |
A028 |
Alemtuzumab
Featured
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. |
216503-57-0 |
DC39262 |
SBP-7455
Featured
SBP-7455 is an orally active dual-specific ULK1/2 autophagy inhibitor with improved binding affinity compared with SBI-0206965. |
1884222-74-5 |
DC39624 |
CP-609754(OSI754)
Featured
CP-609754, also known as CP-609,754, LNK 754 and OSI 754, is a potent arnesyltransferase inhibitor with potential anticancer activity. |
1190094-64-4 |
DC39625 |
(S,R,S)-AHPC-PEG4-NH2 hydrochloride
Featured
VH 032 Linker 2 is a derivative of the proteolysis-targeting chimera technology (PROTAC) building block VHL ligand 1. |
2064292-52-8 |
DC39626 |
BMS-P5
Featured
BMS-P5 is a Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor with pIC50 values in the range of 5-7.5. BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Administration of BMS-P5 to multiple myeloma-be |
1550371-22-6 |
DC39627 |
Aslan003
Featured
ASLAN003 is an orally active and potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC50 of 35 nM for human DHODH enzyme. ASLAN003 inhibits protein synthesis via activation of AP-1 transcription factors. ASLAN003 induces apoptosis and substantially prolongs survival in acute myeloid leukemia (AML) xenograft mice. |
1035688-66-4 |
DC39628 |
beta-Estradiol 17-hemisuccinate
Featured
beta-Estradiol 17-hemisuccinate |
7698-93-3 |
DC39629 |
WC5-2
Featured
WC5-2 is a Resorufin derivatives as high-specificity fluorescent probes in detecting cytochrome P4501A1. The activity of CYP1A1 in different enzyme sources (such as human or animal tissue prepn. liq., recombination expressed CYP1A1 single enzyme, or histocyte biol. samples) can be detected by quant. detn. of fluorescent emission spectrum at 560-630nm with fluorescence detector at excitation wavelength of 480-530nm. |
922722-84-7 |
DC39630 |
ATX inhibitor 1
Featured
ATX inhibitor 1 is a potent ATX (IC50=1.23 nM, FS-3 and 2.18 nM, bis-pNPP) inhibitor. |
2225892-70-4 |
DC39631 |
EGFR-IN-8
Featured
EGFR-IN-8 is a dual EGFR and c-Met inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. |
2407957-87-1 |